Cempra rises on first Phase III solithromycin results
This article was originally published in Scrip
Cempra gained 7.3% to close at $24.55 per share on 5 January after the company revealed during the first weekend of 2015 that its antibiotic solithromycin proved non-inferior to moxifloxacin in the treatment of community acquired bacterial pneumonia (CABP) – including some patients that may normally require hospitalization – in a Phase III clinical trial.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.